NASDAQ$DVAX

Dynavax Technologies Corp · Q1 2023 earnings

Q1 2023 earnings · · Investor relations

Briefing

Reported financial results for the quarter ended March 31, 2023.

Dynavax reported a first quarter 2023 total revenue of $46.9 million, which includes HEPLISAV-B vaccine product revenue of $43.5 million, a 109% increase compared to the first quarter of 2022. The company's cash and investments were $652 million at quarter end and expects positive free cash flow in 2023.

  • HEPLISAV-B vaccine net product revenue increased 109% year-over-year to $43.5 million in the first quarter of 2023
  • Reaffirming HEPLISAV-B net product revenue guidance for full year 2023 of between $165–$185 million, representing annual revenue growth of 30-47%
  • Strengthened balance sheet with cash and investments of $652 million at quarter end
  • Expects positive free cash flow in 2023

Headline financials

Total Revenue

$46.6M

Previous: $112M-58.5%
EPS (adj)

-$0.19

Previous: $0.22-186.4%
HEPLISAV-B Market Share (US)

37.0%

Previous: 26.0%+42.3%
Capital Expenditures

-$1.28M

Previous: -$1.36M+5.5%
Free Cash Flow

$26.3M

Previous: -$51.8M+150.8%
Net Income

-$24.3M

Previous: $32.9M-174.0%
Operating Income

-$30.2M

Previous: $30.8M-198.3%
Gross Profit

$31.9M

Previous: $72.5M-56.0%
Cash & Equivalents

$652M

Previous: $503M+29.6%
Total Assets

$970M

Previous: $1.01B-3.9%
Stock-Based Comp

$10M

Previous: $7.65M+31.2%

Revenue & EPS history

Dynavax · Revenue · Quarterly

$46.6M

Q1 2023-58.5%vs Q1 2022
Beat estimate in 10 of 15 quarters(67%)
ActualEstimate

Revenue by segment

Dynavax · $69.5M total across 2 segments · Q3 2023

  • HEPLISAV-B Net Product Revenue
    $62.3M+66.1%
  • Other Revenue
    $7.2M

Forward guidance

Full year 2023 financial guidance is reiterated and consists of the following expectations:

Tailwinds

  • HEPLISAV-B net product revenue between approximately $165 - $185 million
  • Research and development expenses between approximately $55 - $70 million
  • Selling, general and administrative expenses between approximately $135 - $155 million

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 16 quarterly earnings reports · overlaid with Q1 2023

Historical avgQ1 2023

-0.6%

Avg return

Earnings day

+1.2%

Avg return

5 days after

+0.9%

Avg return

30 days after

49%

31 / 63 earnings

Positive

+18.1%

Q1 2019

Best reaction

-29.1%

Q4 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025
Q3 2025-1.5%+2.4%-1.0%
Q2 2025-6.7%-2.2%-9.0%
Q1 2025-11.0%-9.6%-6.1%
Q4 2024+0.0%+2.5%+3.6%
Q3 2024+5.9%+9.6%+4.5%
Q2 2024+6.8%+10.1%+7.2%
Q1 2024-6.4%-6.2%+2.6%
Q4 2023+2.3%+4.3%-1.4%
Q3 2023+0.9%-5.5%-2.8%
Q2 2023+7.1%+10.0%+7.4%
Q1 2023+4.8%+7.0%+9.0%
Q4 2022-5.0%-5.5%-9.4%
Q3 2022+11.6%+10.3%+12.6%
Q2 2022+17.8%+20.7%-20.6%
Q1 2022-4.3%-12.0%+29.7%
Q4 2021-2.2%-16.1%-11.8%
Q3 2021-22.8%
Q2 2021+6.1%
Q1 2021+9.7%
Q4 2020-6.7%
Q3 2020+0.5%
Q2 2020-13.5%
Q1 2020-8.8%
Q4 2019-29.1%
Q3 2019-5.4%
Q2 2019+5.2%
Q1 2019+18.1%
Q4 2018-7.8%
Q3 2018+2.2%
Q2 2018+5.8%
Q1 2018-5.0%
Q4 2017-0.3%
Q3 2017+6.4%
Q2 2017+12.7%
Q1 2017+0.9%
Q4 2016-2.5%
Q3 2016+6.7%
Q2 2016-2.3%
Q1 2016+8.7%
Q4 2015-4.6%
Q3 2015-1.5%
Q2 2015+10.8%
Q1 2015+1.9%
Q4 2014+0.1%
Q3 2014-1.9%
Q2 2014-9.2%
Q1 2014-3.9%
Q4 2013-4.2%
Q3 2013+4.5%
Q2 2013+2.4%
Q1 2013-5.2%
Q4 2012+2.1%
Q3 2012+0.5%
Q2 2012+2.4%
Q1 2012-3.6%
Q4 2011+3.1%
Q3 2011-14.0%
Q2 2011-14.6%
Q1 2011-1.1%
Q4 2010-2.5%
Q3 2010+2.4%
Q2 2010-8.1%
Q1 2010+7.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro